Drug class
Inflammatory Bowel Agents
Inflammatory bowel agents represent a broad therapeutic and formulary category comprising pharmacologically diverse medications used to treat chronic inflammatory diseases of the gastrointestinal tract. Read more about Inflammatory Bowel Agents
230 drugs in this class 81 manufacturers
Drugs in Inflammatory Bowel Agents
AMJEVITA(CF) (adalimumab-atto)
AMJEVITA(CF) AUTOINJECTOR (adalimumab-atto)
WEZLANA (ustekinumab-auub)
ABRILADA(CF) PEN (2 PACK) (adalimumab-afzb)
MESALAMINE DR (mesalamine)
MESALAMINE ER (mesalamine)
SIMLANDI(CF) (adalimumab-ryvk)
SULFASALAZINE
Inflammatory bowel agents represent a broad therapeutic and formulary category comprising pharmacologically diverse medications used to treat chronic inflammatory diseases of the gastrointestinal tract.
Rather than operating via a single mechanism of action, medications in this grouping reduce mucosal inflammation and modulate aberrant immune responses through local prostaglandin and leukotriene inhibition, broad immunosuppression, cytokine antagonism, or targeted cellular signaling blockade.
Their primary therapeutic role is to induce and maintain clinical and endoscopic remission in patients with ulcerative colitis and Crohn's disease.
-
fda.gov
Inflammatory bowel agents represent a broad therapeutic and formulary category comprising pharmacologically diverse medications used to treat chronic inflammatory diseases of the gastrointestinal tract
-
nih.gov
Inflammatory bowel agents represent a broad therapeutic and formulary category comprising pharmacologically diverse medications used to treat chronic inflammatory diseases of the gastrointestinal tract Rather than operating via a single mechanism of action, medications in this grouping reduce mucosal inflammation and modulate aberrant immune responses through local prostaglandin and leukotriene inhibition, broad immunosuppression, cytokine antagonism, or targeted cellular signaling blockade Thei...
-
medlineplus.gov
Rather than operating via a single mechanism of action, medications in this grouping reduce mucosal inflammation and modulate aberrant immune responses through local prostaglandin and leukotriene inhibition, broad immunosuppression, cytokine antagonism, or targeted cellular signaling blockade
-
fda.gov
Their primary therapeutic role is to induce and maintain clinical and endoscopic remission in patients with ulcerative colitis and Crohn's disease
-
nih.gov
Their primary therapeutic role is to induce and maintain clinical and endoscopic remission in patients with ulcerative colitis and Crohn's disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.